

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
The Spectranetics Corporation		02/25/2011	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	Wells Fargo Bank, National Association		
Street Address:	1740 Broadway		
Internal Address:	MAC C7300-210		
City:	Denver		
State/Country:	COLORADO		
Postal Code:	80274		
Entity Type:	National Association: UNITED STATES		
PROPERTY NUMBERS Total: 23			
Property Type	Number	Word Mark	
Registration Number:	3832560	TORQMAX	
Registration Number:	3782516	TURBO-TANDEM	
Registration Number:	3768583	VISISHEATH	
Registration Number:	3741047	CROSS-PILOT	
Registration Number:	3737800	SPNC	
Registration Number:	3562200	LLD EZ	
Registration Number:	3386550	THROMCAT	
Registration Number:	3367148	TURBO ELITE	
Registration Number:	3354066	TURBO-BOOSTER	
Registration Number:	3140487	CLIRCROSS	
Registration Number:	3072724	SLS	
Registration Number:	3037530	CLEARS	
Registration Number:	2928706	QUICK-CROSS	

CH \$590.00 3832560

900188866

TRADEMARK
REEL: 004518 FRAME: 0514

Registration Number:	2922727	LLD
Registration Number:	2890374	CLIRPATH
Registration Number:	2654938	SAFE-CROSS
Registration Number:	1823660	ELCA
Registration Number:	1741114	EXTREME
Registration Number:	1741106	SPECTRANETICS
Registration Number:	1732806	SPECTRAGLIDE
Registration Number:	1723546	CVX-300
Registration Number:	1717855	SPECTRAGLIDE
Registration Number:	1717853	SPECTRANETICS

CORRESPONDENCE DATA

Fax Number: (435)214-3811

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 435-214-3807

Email: mjones@markuswilliams.com

Correspondent Name: Melinda Jones

Address Line 1: 2720 Homestead Road, Suite 150

Address Line 4: Park City, UTAH 84098

ATTORNEY DOCKET NUMBER:	10918.544
NAME OF SUBMITTER:	Melinda Jones
Signature:	/mej/
Date:	04/08/2011

Total Attachments: 16

source=Spectranetics Patent and Trademark Security Agreement#page1.tif
source=Spectranetics Patent and Trademark Security Agreement#page2.tif
source=Spectranetics Patent and Trademark Security Agreement#page3.tif
source=Spectranetics Patent and Trademark Security Agreement#page4.tif
source=Spectranetics Patent and Trademark Security Agreement#page5.tif
source=Spectranetics Patent and Trademark Security Agreement#page6.tif
source=Spectranetics Patent and Trademark Security Agreement#page7.tif
source=Spectranetics Patent and Trademark Security Agreement#page8.tif
source=Spectranetics Patent and Trademark Security Agreement#page9.tif
source=Spectranetics Patent and Trademark Security Agreement#page10.tif
source=Spectranetics Patent and Trademark Security Agreement#page11.tif
source=Spectranetics Patent and Trademark Security Agreement#page12.tif
source=Spectranetics Patent and Trademark Security Agreement#page13.tif
source=Spectranetics Patent and Trademark Security Agreement#page14.tif
source=Spectranetics Patent and Trademark Security Agreement#page15.tif
source=Spectranetics Patent and Trademark Security Agreement#page16.tif

PATENT AND TRADEMARK SECURITY AGREEMENT

This Patent and Trademark Security Agreement (this "Agreement"), dated as of February 25, 2011, is made by and between The Spectranetics Corporation, a Delaware corporation having a business location at the address set forth below next to its signature ("Company"), and Wells Fargo Bank, National Association ("Wells Fargo"), having a business location at the address set forth below next to its signature.

Recitals

Company and Wells Fargo are parties to a Credit and Security Agreement (as amended, supplemented or restated from time to time, the "Credit Agreement") dated the same date as this Agreement, setting forth the terms on which Wells Fargo may now or hereafter extend credit to or for the account of Company.

As a condition to extending credit to or for the account of Company, Wells Fargo has required the execution and delivery of this Agreement by Company.

ACCORDINGLY, in consideration of the mutual covenants contained in the Loan Documents and herein, the parties hereby agree as follows:

1. Definitions. All terms defined in the Recitals hereto or in the Credit Agreement that are not otherwise defined herein shall have the meanings given to them in the Credit Agreement. In addition, the following terms have the meanings set forth below:

"Patents" means all of Company's right, title and interest in and to U.S. patents or applications for U.S. patents, together with all fees or royalties with respect to each, and including without limitation the right to sue for past infringement and damages therefor, and licenses thereunder, all as presently existing or hereafter arising or acquired, including without limitation the patents listed on Exhibit A.

"Security Interest" has the meaning given in Section 2.

"Trademarks" means all of Company's right, title and interest in and to: (i) trademarks, service marks, collective membership marks, U.S. registrations and applications for U.S. registration for each, and the respective goodwill associated with each, (ii) licenses, fees or royalties with respect to each, (iii) the right to sue for past, present and future infringement, dilution and damages therefor, and (iv) licenses thereunder, all as presently existing or hereafter arising or acquired, including, without limitation, the marks listed on Exhibit B.

2. Security Interest. Company hereby irrevocably pledges and assigns to, and grants Wells Fargo a security interest (the "Security Interest") with power of sale to the extent permitted by law, in the Patents and in the Trademarks to secure payment of the Indebtedness. As set forth in the Credit Agreement, the Security Interest is coupled with a security interest in substantially all of the personal property of Company. This Agreement grants only the Security Interest herein described, is not intended to and does not affect any present transfer of title of any

trademark registration or application and makes no assignment and grants no right to assign or perform any other action with respect to any intent to use trademark application, unless such action is permitted under 15 U.S.C. § 1060.

3. Representations, Warranties and Agreements. Company represents, warrants and agrees as follows:

(a) **Existence; Authority.** Company is a corporation duly incorporated, validly existing and in good standing under the laws of its state of incorporation and this Agreement has been duly and validly authorized by all necessary corporate action on the part of Company.

(b) **Patents.** Exhibit A accurately lists all Patents owned by Company as of the date hereof, or to which Company has a right as of the date hereof to have assigned to it, and accurately reflects the existence of applications for Patents owned by Company as of the date hereof. If after the date hereof, Company owns, controls or has a right to have assigned to it any Patents not listed on Exhibit A, or if Exhibit A ceases to accurately reflect the existence and status of applications and letters patent pertaining to the Patents, then Company shall within 60 days provide written notice to Wells Fargo with a replacement Exhibit A, which upon acceptance by Wells Fargo shall become part of this Agreement.

(c) **Trademarks.** Exhibit B accurately lists all Trademarks owned by Company as of the date hereof and accurately reflects the existence of all applications for Trademark registrations as of the date hereof; provided, however, that Exhibit B need not list common law marks (i.e., Trademarks for which there are no applications or registrations) which are not material to Company's or any Affiliate's business(es). If after the date hereof, Company owns or controls any Trademarks not listed on Exhibit B (other than common law marks which are not material to Company's or any Affiliate's business(es)), or if Exhibit B ceases to accurately reflect the existence and status of applications and registrations pertaining to the Trademarks, then Company shall promptly provide written notice to Wells Fargo with a replacement Exhibit B, which upon acceptance by Wells Fargo shall become part of this Agreement.

(d) **Affiliates.** As of the date hereof, and except as indicated on Exhibit A, no Affiliate owns, controls, or has a right to have assigned to it any items that would, if such item were owned by Company, constitute Patents or Trademarks. If after the date hereof any Affiliate owns, controls, or has a right to have assigned to it any such items, then Company shall promptly either: (i) cause such Affiliate to assign all of its rights in such item(s) to Company; or (ii) notify Wells Fargo of such item(s) and cause such Affiliate to execute and deliver to Wells Fargo a patent and trademark security agreement substantially in the form of this Agreement.

(e) **Title.** Company has absolute title to each Patent and each Trademark listed on Exhibits A and B, free and clear of all Liens except Permitted Liens. Company (i) will have, at the time Company acquires any rights in Patents or Trademarks hereafter arising, absolute title to each such Patent or Trademark free and clear of all Liens except

Permitted Liens, and (ii) will keep all Patents and Trademarks free and clear of all Liens except Permitted Liens.

(f) **No Sale.** Except as permitted in the Credit Agreement, Company will not assign, transfer, encumber or otherwise dispose of the Patents or Trademarks, or any interest therein, without Wells Fargo's prior written consent.

(g) **Defense.** Company will at its own expense and using commercially reasonable efforts, protect and defend the Patents and Trademarks against all claims or demands of all Persons other than those holding Permitted Liens.

(h) **Maintenance.** Company will at its own expense maintain the Patents and the Trademarks to the extent reasonably advisable in its business including, but not limited to, filing all applications to obtain letters patent or trademark registrations and all affidavits, maintenance fees, annuities, and renewals possible with respect to letters patent, trademark registrations and applications therefor. Company covenants that it will not abandon nor fail to pay any maintenance fee or annuity due and payable on any Patent or Trademark, nor fail to file any required affidavit or renewal in support thereof, without first providing Wells Fargo: (i) sufficient written notice, of at least 30 days, to allow Wells Fargo to timely pay any such maintenance fees or annuities which may become due on any Patents or Trademarks, or to file any affidavit or renewal with respect thereto, and (ii) a separate written power of attorney or other authorization to pay such maintenance fees or annuities, or to file such affidavit or renewal, should such be necessary or desirable.

(i) **Wells Fargo's Right to Take Action.** If Company fails to perform or observe any of its covenants or agreements set forth in this Section 3, and if such failure continues for a period of ten (10) calendar days after Wells Fargo gives Company written notice thereof (or, in the case of the agreements contained in subsection (h), immediately upon the occurrence of such failure, without notice or lapse of time), or if Company notifies Wells Fargo that it intends to abandon a Patent or Trademark other than a Patent or Trademark that Company has reasonably determined is no longer useful in its business, Wells Fargo may (but need not) perform or observe such covenant or agreement or take steps to prevent such intended abandonment on behalf and in the name, place and stead of Company (or, at Wells Fargo's option, in Wells Fargo's own name) and may (but need not) take any and all other actions which Wells Fargo may reasonably deem necessary to cure or correct such failure or prevent such intended abandonment.

(j) **Costs and Expenses.** Except to the extent that the effect of such payment would be to render any loan or forbearance of money usurious or otherwise illegal under any applicable law, Company shall pay Wells Fargo on demand the amount of all moneys expended and all costs and expenses (including reasonable attorneys' fees and disbursements) incurred by Wells Fargo in connection with or as a result of Wells Fargo's taking action under subsection (i) or exercising its rights under Section 6, together with interest thereon from the date expended or incurred by Wells Fargo at the Default Rate.

(k) **Power of Attorney.** To facilitate Wells Fargo's taking action under subsection (i) and exercising its rights under Section 6, Company hereby irrevocably appoints (which appointment is coupled with an interest) Wells Fargo, or its delegate, as the attorney-in-fact of Company with the right (but not the duty) from time to time to create, prepare, complete, execute, deliver, endorse or file, in the name and on behalf of Company, any and all instruments, documents, applications, financing statements, and other agreements and writings required to be obtained, executed, delivered or endorsed by Company under this Section 3, or, necessary for Wells Fargo, after an Event of Default, to enforce or use the Patents or Trademarks or to grant or issue any exclusive or non-exclusive license under the Patents or Trademarks to any third party, or to sell, assign, transfer, pledge, encumber or otherwise transfer title in or dispose of the Patents or Trademarks to any third party. Company hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. The power of attorney granted herein shall terminate upon the termination of the Credit Agreement as provided therein and the payment and performance of all Indebtedness.

4. **Company's Use of the Patents and Trademarks.** Company shall be permitted to control and manage the Patents and Trademarks, including the right to exclude others from making, using or selling items covered by the Patents and Trademarks and any licenses thereunder, in the same manner and with the same effect as if this Agreement had not been entered into, so long as no Event of Default occurs and remains uncured.

5. **Events of Default.** Each of the following occurrences shall constitute an event of default under this Agreement (herein called "Event of Default"): (a) an Event of Default, as defined in the Credit Agreement, shall occur; or (b) Company shall fail promptly to observe or perform any covenant or agreement herein binding on it; or (c) any of the representations or warranties contained in Section 3 shall prove to have been incorrect in any material respect when made.

6. **Remedies.** Upon the occurrence of an Event of Default and at any time thereafter, Wells Fargo may, at its option, take any or all of the following actions:

(a) Wells Fargo may exercise any or all remedies available under the Credit Agreement.

(b) Wells Fargo may sell, assign, transfer, pledge, encumber or otherwise dispose of the Patents and Trademarks.

(c) Wells Fargo may enforce the Patents and Trademarks and any licenses thereunder, and if Wells Fargo shall commence any suit for such enforcement, Company shall, at the request of Wells Fargo, do any and all lawful acts and execute any and all proper documents required by Wells Fargo in aid of such enforcement.

7. **Miscellaneous.** This Agreement can be waived, modified, amended, terminated or discharged, and the Security Interest can be released, only explicitly in a writing signed by Wells Fargo. A waiver signed by Wells Fargo shall be effective only in the specific instance and for the specific purpose given. Mere delay or failure to act shall not preclude the exercise or

enforcement of any of Wells Fargo's rights or remedies. All rights and remedies of Wells Fargo shall be cumulative and may be exercised singularly or concurrently, at Wells Fargo's option, and the exercise or enforcement of any one such right or remedy shall neither be a condition to nor bar the exercise or enforcement of any other. All notices to be given to Company under this Agreement shall be given in the manner and with the effect provided in the Credit Agreement. Wells Fargo shall not be obligated to preserve any rights Company may have against prior parties, to realize on the Patents and Trademarks at all or in any particular manner or order, or to apply any cash proceeds of Patents and Trademarks in any particular order of application. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed to be an original and all of which counterparts, taken together, shall constitute but one and the same instrument. Delivery of an executed counterpart of this Agreement by telefacsimile or other electronic means shall be equally as effective as delivery of an original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by telefacsimile or other electronic means also shall deliver an original executed counterpart of this Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Agreement. This Agreement shall be binding upon and inure to the benefit of Company and Wells Fargo and their respective participants, successors and assigns and shall take effect when signed by Company and delivered to Wells Fargo, and Company waives notice of Wells Fargo's acceptance hereof. Wells Fargo may execute this Agreement if appropriate for the purpose of filing, but the failure of Wells Fargo to execute this Agreement shall not affect or impair the validity or effectiveness of this Agreement. A carbon, photographic or other reproduction of this Agreement or of any financing statement signed by Company shall have the same force and effect as the original for all purposes of a financing statement. This Agreement shall be governed by the internal law of Colorado without regard to conflicts of law provisions. If any provision or application of this Agreement is held unlawful or unenforceable in any respect, such illegality or unenforceability shall not affect other provisions or applications which can be given effect and this Agreement shall be construed as if the unlawful or unenforceable provision or application had never been contained herein or prescribed hereby. All representations and warranties contained in this Agreement shall survive the execution, delivery and performance of this Agreement and the creation and payment of the Indebtedness.


THE PARTIES WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING BASED ON OR PERTAINING TO THIS AGREEMENT.

[The remainder of this page intentionally left blank.]

IN WITNESS WHEREOF, the parties have executed this Patent and Trademark Security Agreement as of the date written above.

The Spectranetics Corporation
9965 Federal Drive
Colorado Springs, Colorado 80921

THE SPECTRANETICS CORPORATION

By: 
Name: Guy Childs
Its: Chief Financial Officer


Wells Fargo Bank, National Association
MAC C7300-210
1740 Broadway
Denver, Colorado 80274


WELLS FARGO BANK, NATIONAL
ASSOCIATION

By: _____
Name: Karen S. Kenney
Its: Authorized Signatory

STATE OF COLORADO)
)
COUNTY OF EL PASO)

The foregoing instrument was acknowledged before me this 25th day of February, 2011, by Guy Childs, the Chief Financial Officer of The Spectranetics Corporation, a Delaware corporation, on behalf of the corporation.




Notary Public
My Commission exp. Sept. 21, 2012

STATE OF COLORADO)
)
CITY AND COUNTY OF DENVER)

The foregoing instrument was acknowledged before me this ____ day of _____, 2011, by Karen S. Kenney, an Authorized Signatory of Wells Fargo Bank, National Association, on behalf of the national association.

Notary Public

IN WITNESS WHEREOF, the parties have executed this Patent and Trademark Security Agreement as of the date written above.

The Spectranetics Corporation
9965 Federal Drive
Colorado Springs, Colorado 80921

THE SPECTRANETICS CORPORATION

By: _____
Name: Guy Childs
Its: Chief Financial Officer

Wells Fargo Bank, National Association
MAC C7300-210
1740 Broadway
Denver, Colorado 80274

WELLS FARGO BANK, NATIONAL
ASSOCIATION

By: Karen Kenney
Name: Karen S. Kenney
Its: Authorized Signatory

STATE OF COLORADO)
)
COUNTY OF EL PASO)


The foregoing instrument was acknowledged before me this ____ day of _____, 2011, by Guy Childs, the Chief Financial Officer of The Spectranetics Corporation, a Delaware corporation, on behalf of the corporation.

Notary Public

STATE OF COLORADO)
)
CITY AND COUNTY OF DENVER)

The foregoing instrument was acknowledged before me this 9th day of FEBRUARY, 2011, by Karen S. Kenney, an Authorized Signatory of Wells Fargo Bank, National Association, on behalf of the national association.

Sheila M. Jordan
Notary Public



Signature Page to Patent and Trademark Security Agreement

TRADEMARK
REEL: 004518 FRAME: 0522

EXHIBIT A
UNITED STATES ISSUED PATENTS

<u>Title</u>	<u>Patent Number</u>	<u>Issue Date</u>
APPARATUS AND METHODS FOR DIRECTIONAL DELIVERY OF LASER ENERGY	7,846,153	December 7, 2010
THROMBECTOMY AND SOFT DEBRIS REMOVAL DEVICE	7,666,161	February 23, 2010
ENDOCARDIAL LEAD CUTTING APPARATUS	7,651,503	January 26, 2010
APPARATUS AND METHODS FOR DIRECTIONAL DELIVERY OF LASER ENERGY	7,572,254	August 11, 2009
RADIO FREQUENCY GUIDE WIRE ASSEMBLY WITH OPTICAL COHERENCE REFLECTOMETRY GUIDANCE	7,563,262	July 21, 2009
LEAD LOCKING DEVICE AND METHOD	7,499,756	March 3, 2009
SHAPEABLE INTRALUMINAL DEVICE AND METHOD THEREFOR	7,303,533	December 4, 2007
EXPANDABLE LASER CATHETER	7,288,087	October 30, 2007
PROXIMAL COUPLER FOR OPTICAL FIBERS	7,050,692	May 23, 2006
METHOD FOR GUIDING A MEDICAL INSTRUMENT THROUGH A BODY	6,970,732	November 29, 2005
DEFLECTING CATHETER	6,951,554	October 4, 2005
RADIO FREQUENCY GUIDE WIRE ASSEMBLY WITH OPTICAL COHERENCE REFLECTOMETRY GUIDANCE	6,852,109	February 8, 2005
METHOD AND APPARATUS FOR DETERMINING NEOVASCULAR FLOW THROUGH TISSUE IN A VESSEL	6,842,639	January 11, 2005

<u>Title</u>	<u>Patent Number</u>	<u>Issue Date</u>
LEAD LOCKING DEVICE AND METHOD	6,772,014	August 3, 2004
CATHETER HANDLE FOR CONTROLLING THE ADVANCEMENT OF A GUIDE WIRE	6,752,800	June 22, 2004
SYSTEMS AND METHODS FOR STEERING A CATHETER THROUGH BODY TISSUE	6,663,621	December 16, 2003
EXPANDABLE LASER CATHETER	6,485,485	November 26, 2002
SYSTEMS FOR GUIDING A MEDICAL INSTRUMENT THROUGH A BODY	6,463,313	October 8, 2002
CATHETER FOR CONTROLLING THE ADVANCEMENT OF A GUIDE WIRE	6,394,976	May 28, 2002
LEAD LOCKING DEVICE AND METHOD	6,324,434	November 27, 2001
SYSTEM AND METHOD FOR CONTROLLING TISSUE ABLATION	6,228,076	May 8, 2001
GUIDE WIRE ASSEMBLY	6,193,676	February 27, 2001
LEAD LOCKING DEVICE AND METHOD	6,167,315	December 26, 2000
EXPANDABLE LASER CATHETER	6,106,515	August 22, 2000
SYSTEMS AND METHODS FOR GUIDING A MEDICAL INSTRUMENT THROUGH A BODY	6,063,093	May 16, 2000
SYSTEMS AND METHODS FOR GUIDING A MEDICAL INSTRUMENT THROUGH A BODY	6,048,349	April 11, 2000
SYSTEMS AND METHODS FOR STEERING A CATHETER THROUGH BODY TISSUE	6,013,072	January 11, 2000
PHOTOTHERAPY DEVICE AND METHOD	5,976,124	November 2, 1999
ASSEMBLIES AND METHODS FOR ADVANCING A GUIDE WIRE THROUGH BODY TISSUE	5,951,482	September 14, 1999
CATHETER FOR LASER TREATMENT OF ATHEROSCLEROTIC PLAQUE AND OTHER TISSUE ABNORMALITIES	5,916,210	June 29, 1999

<u>Title</u>	<u>Patent Number</u>	<u>Issue Date</u>
PHOTOACOUSTIC DRUG DELIVERY	5,836,940	November 17, 1998
METHOD FOR CONTEMPORANEOUS APPLICATION OF LASER ENERGY AND LOCALIZED PHARMACOLOGIC THERAPY	5,817,144	October 6, 1998
FLUID CORE LASER ANGIOSCOPE	5,573,531	November 12, 1996
METHOD FOR CONTEMPORANEOUS APPLICATION OF LASER ENERGY AND LOCALIZED PHARMACOLOGIC THERAPY	5,571,151	November 5, 1996
CATHETER FOR DELIVERY OF ELECTRIC ENERGY AND A PROCESS FOR MANUFACTURING SAME	5,836,946	November 17, 1998
CATHETER FOR DELIVERY OF ELECTRIC ENERGY AND A PROCESS FOR MANUFACTURING SAME	5,824,026	October 20, 1998
FIBER OPTIC GUIDE WIRE AND SUPPORT CATHETER THEREFOR	5,643,251	July 1, 1997
FIBER OPTIC GUIDE WIRE AND SUPPORT CATHETER THEREFOR	5,514,128	May 7, 1996
MEDICAL CATHETER USING OPTICAL FIBERS THAT TRANSMIT BOTH LASER ENERGY AND ULTRASONIC IMAGING SIGNALS	5,486,170	January 23, 1996
TISSUE ABLATING DEVICE HAVING A DEFLECTABLE ABLATION AREA AND METHOD OF USING SAME	5,484,433	January 16, 1996
APPARATUS AND METHOD FOR ASPIRATING INTRAVASCULAR, PULMONARY AND CARDIAC OBSTRUCTIONS	5,476,450	December 19, 1995
GUIDANCE AND DELIVERY SYSTEM FOR HIGH-ENERGY PULSED LASER LIGHT	5,470,330	November 28, 1995
FIBER OPTIC CATHETER WITH SHORTENED GUIDE WIRE LUMEN	5,456,680	October 10, 1995

<u>Title</u>	<u>Patent Number</u>	<u>Issue Date</u>
PREIONIZER FOR LASER ASSEMBLY	5,438,587	August 1, 1995
RADIOPAQUE TIP MARKER FOR ALIGNMENT OF A CATHETER WITHIN A BODY	5,429,617	July 4, 1995
FIBER OPTIC CATHETER WITH TWISTABLE TIP	5,429,604	July 4, 1995
OPTICAL CATHETER WITH STRANDED FIBERS	5,415,653	May 16, 1995
HALOGEN COMPATIBLE LASER HEAD	5,412,682	May 2, 1995
METHOD AND APPARATUS FOR LINEARLY SCANNING ENERGY OVER AN OPTICAL FIBER ARRAY AND COUPLER FOR COUPLING ENERGY TO THE OPTICAL FIBER ARRAY	5,400,428	March 21, 1995
EXPANDABLE FIBEROPTIC CATHETER AND METHOD OF INTRALUMINAL LASER TRANSMISSION	5,395,361	March 7, 1995
APPARATUS AND METHOD FOR OPTICALLY CONTROLLING THE OUTPUT ENERGY OF A PULSED LASER SOURCE	5,383,199	January 17, 1995
TURN LIMITER FOR A CATHETER WITH TWISTABLE TIP	5,352,197	October 4, 1994
MEDICAL CATHETER USING OPTICAL FIBERS THAT TRANSMIT BOTH LASER ENERGY AND ULTRASONIC IMAGING SIGNALS	5,350,377	September 27, 1994
POLARIZING DEVICE WITH OPTICALLY CONTACTED THIN FILM INTERFACE FOR HIGH POWER DENSITY ULTRAVIOLET LIGHT	5,339,441	August 16, 1994
MOUNT FOR OPTICAL FIBERS	5,321,783	June 14, 1994
APPARATUS AND METHOD FOR SOFT FOCUSING ENERGY INTO AN OPTICAL	5,315,614	May 24, 1994

<u>Title</u>	<u>Patent Number</u>	<u>Issue Date</u>
FIBER ARRAY		
FIBEROPTIC COUPLER	5,267,993	December 7, 1993
TWO-PIECE TIP FOR FIBER OPTIC CATHETER	5,263,952	November 23, 1993
OPTICAL FIBER CATHETER WITH SPACED OPTICAL FIBER	5,250,045	October 5, 1993

UNITED STATES PATENT APPLICATIONS AND ADDITIONS



<u>Title</u>	<u>Serial Number</u>	<u>Filing Date</u>
OFFSET CATHETER	12/333,427	December 12, 2008
ECCENTRIC BALLOON LASER CATHETER	12/337,190	December 17, 2008
THROMBECTOMY AND SOFT DEBRIS REMOVAL DEVICE	12/705,332	February 12, 2010
BIASING LASER CATHETER: MONORAIL DESIGN	12/265,441	November 5, 2008
TAPERED LIQUID LIGHT GUIDE	12/176,886	July 21, 2008
LASER CATHETER CALIBRATOR	11/946,376	November 28, 2007
LIQUID LIGHT-GUIDE CATHETER WITH OPTICALLY DIVERGING TIP	12/254,254	October 20, 2008
LASER-ASSISTED GUIDEWIRE HAVING A VARIABLE STIFFNESS SHAFT	12/296,270	April 4, 2007
TUNABLE NANOPARTICLE TAGS TO ENHANCE TISSUE RECOGNITION	11/966,214	December 28, 2007
RAPID EXCHANGE BIAS LASER CATHETER DESIGN	12/337,232	December 17, 2008
LOW-LOSS POLARIZED LIGHT DIVERSION	11/952,223	December 7, 2007

<u>Title</u>	<u>Serial Number</u>	<u>Filing Date</u>
INTRA-VASCULAR DEVICE WITH PRESSURE DETECTION CAPABILITIES USING PRESSURE SENSITIVE MATERIAL	11/937,583	November 9, 2007
LIQUID LIGHT GUIDE CATHETER HAVING BIOCOMPATIBLE LIQUID LIGHT GUIDE MEDIUM	11/923,488	October 24, 2007
MULTI-PORT LIGHT DELIVERY CATHETER AND METHODS FOR THE USE THEREOF	11/616,214	December 26, 2006
RETRACTABLE SEPARATING SYSTEMS AND METHODS	11/615,006	December 22, 2006
TISSUE SEPARATING SYSTEMS AND METHODS	11/615,005	December 22, 2006
THROMBECTOMY AND SOFT DEBRIS REMOVAL DEVICE	11/871,908	October 12, 2007
SHAPEABLE INTRALUMINAL DEVICE AND METHOD THEREFOR	11/949,987	December 4, 2007
LASER-ASSISTED GUIDEWIRE HAVING A VARIABLE STIFFNESS SHAFT	11/696,618	April 4, 2007
THROMBECTOMY AND SOFT DEBRIS REMOVAL DEVICE	10/832,830	April 27, 2004
LEAD LOCKING DEVICE AND METHOD	10/877,190	June 25, 2004
ENDOCARDIAL LEAD CUTTING APPARATUS	11/187,553	7/22/2005
ENDOCARDIAL LEAD REMOVING APPARATUS	11/190,550	2/27/2005
ENDOCARDIAL LEAD REMOVING APPARATUS	11/484,825	7/11/2006
TUNABLE NANOPARTICLE TAGS TO ENHANCE TISSUE RECOGNITION	11/966,214	12/28/2007
EXPANDABLE LASER CATHETER	11/888,027	7/30/2007
FORCE ASSESSMENT DEVICE AND METHOD FOR LEAD EXTRACTION	12/392,944	2/25/2009

<u>Title</u>	<u>Serial Number</u>	<u>Filing Date</u>
SNARING SYSTEMS AND METHODS	12/878,648	9/9/2010
CARDIOVASCULAR IMAGING SYSTEM	12/649,759	12/30/2009

EXHIBIT B**UNITED STATES ISSUED TRADEMARKS, SERVICE MARKS
AND COLLECTIVE MEMBERSHIP MARKS****REGISTRATIONS**

<u>Mark</u>	<u>Registration Number</u>	<u>Registration Date</u>
TORQMAX	3,832,560	August 10, 2010
TURBO-TANDEM	3,782,516	April 27, 2010
VISISHEATH	3,768,583	March 30, 2010
CROSS-PILOT	3,741,047	January 19, 2010
SPNC	3,737,800	January 12, 2010
LLD EZ	3,562,200	January 13, 2009
ThromCat	3,386,550	February 19, 2008
TURBO ELITE	3,367,148	January 8, 2008
TURBO-BOOSTER	3,354,066	December 11, 2007
CLIRCROSS	3,140,487	September 5, 2006
SLS	3,072,724	March 28, 2006
CLEARs	3,037,530	January 3, 2006
QUICK-CROSS	2,928,706	March 1, 2005
LLD	2,922,727	February 1, 2005
CLIRPATH	2,890,374	September 28, 2004
SAFE-CROSS	2,654,938	November 26, 2002
ELCA	1,823,660	February 22, 1994
EXTREME	1,741,114	December 22, 1992
SPECTRANETICS	1,741,106	December 22, 1992

<u>Mark</u>	<u>Registration Number</u>	<u>Registration Date</u>
SPECTRAGLIDE	1,732,806	November 17, 1992
CVX-300	1,723,546	October 13, 1992
	1,717,855	September 22, 1992
	1,717,853	September 22, 1992

APPLICATIONS

NONE

COLLECTIVE MEMBERSHIP MARKS

NONE

UNREGISTERED MARKS

NONE